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Abstract
Aims/hypothesis Subcutaneous immunisation with the 9–23
amino acid region of the insulin B chain (B:9-23) in
incomplete Freund’s adjuvant (IFA) can protect the major-
ity of 4- to 6-week-old prediabetic NOD mice and is
currently in clinical trials. Here we analysed the effect of
B:9-23/IFA immunisation at later stages of the disease and
the underlying mechanisms.
Methods NOD mice were immunised once s.c. with B:9-
23/IFA at 5 or 9 weeks of age, or when blood glucose
reached 10 mmol/l or higher. Diabetes incidence was
followed in addition to variables such as regulatory T cell
(Treg) induction, cytokine production (analysed by Elispot)
and emergence of pathogenic CD8
+/NRP-V7
+ cells.
Results A single B:9-23/IFA immunisation protected the
majority of NOD mice at advanced stages of insulitis, but
not after blood glucose reached 13.9 mmol/l. It increased
Treg numbers and lost its protective effect after IFNγ or IL-
10 neutralisation, but not in the absence of IL-4.
CD4
+CD25
+ and to a lesser extent IFNγ-producing cells
from mice protected by B:9-23/IFA induced tolerance upon
transfer into new NOD animals, indicating that a dominant
Treg-mediated effect was operational. Reduced numbers of
CD8
+/NRP-V7
+ memory T cells coincided with protection
from the disease.
Conclusions/interpretation Protection from diabetes after
B:9-23/IFA immunisation cannot be achieved once diabetes
is fully established, but can be achieved at most prediabetic
stages of the disease. Protection is mediated by Tregs that
require IFNγ and IL-10. These findings should provide
important guidance for ongoing human trials, especially for
the development of suitable T cell biomarkers.
Keywords B:9-23.IFNγ.IL-4.IL-10.Incomplete
Freund’s adjuvant.Tregs.Type 1 diabetes
Abbreviations
APC Antigen-presenting cell
B:9-23 9-23 Amino acid region of the insulin B
chain
CTLA-4 Cytotoxic T lymphocyte antigen 4
FOXP3 Forkhead box p3
ICCS Intracellular cytokine staining
IFA Incomplete Freund’s adjuvant
IGRP Islet-specific glucose-6-phosphatase
catalytic subunit-related protein
PDLN Pancreatic draining lymph nodes
Introduction
Type 1 diabetes is one of the most common autoimmune
diseases affecting the lives of millions of patients, among
them children. As with most autoimmune diseases, many
different autoantigens can be involved in the pathogenic
response against the insulin-producing beta cells of the
pancreas. In humans and mice, islet autoantibody specific-
ities and epitopes for CD4
+ and CD8
+ T cells recognising
insulin, GAD, islet tyrosine phosphatase IA-2 and islet-
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protein (IGRP) have been identified [1–4], but it is unclear
which of these autoantigens are crucial for diabetes
development. In NOD mice, the 9–23 amino acid region
of the insulin B chain (B:9-23) is the dominant epitope
involved in initiation of the disease [5–7]. In light of recent
advances, various beta cell-specific therapeutic approaches
have been developed and tested in animal models of
diabetes, primarily in NOD mice [8]. Due to their specific
immune-modulating effects, antigen-specific approaches
represent preferable avenues for immune intervention [9].
Antigen-specific therapies can be applied before or after
diabetes onset, depending on their efficacy [8–11]. The goal
of beta cell antigen-specific approaches is to ‘re-educate’
the immune system to stop it attacking the beta cells of the
pancreas [9, 12, 13]. A large panel of autoantigenic
epitopes has been established for humans and mice.
Insulin-based interventions have shown very promising
results in mice [14–17] and based on these findings, human
clinical trials with insulin are currently on the way [18].
Prevention of diabetes following immunisation with insulin
or insulin-derived epitopes has succeeded in many exper-
imental settings, e.g. after intramuscular DNA vaccination,
after oral treatment, or after intranasal and s.c. peptide
vaccination in the presence or absence of enhancers such as
incomplete Freund’s adjuvant (IFA). For B:9-23 immunisa-
tion, most of these approaches have shown protection from
diabetes, with the precise mechanism being unknown [14–
17, 19–22]. The great importance of better defining the
underlying mechanisms is that this could provide a basis for
defining biomarkers that would help monitor the effect of
B:9-23 immunisation on the progression of beta cell
autoimmunity in clinical trials.
With respect to s.c. B:9-23/IFA immunisation, all
previously published studies were conducted at a rather
early stage of the disease in the NOD mouse (4–6 weeks
old) [14, 15]. We reasoned that it would be important to
carry out additional B:9-23/IFA immunisation studies at a
later, more advanced stage of the disease (9 weeks old and
recent-onset) in order to better reflect the human scenario,
where prediabetic patients with different degrees of beta
cell loss and targeted autoantigens are being recruited. Of
great importance for current clinical trials currently imple-
menting B:9-23/IFA immunisation after diabetes onset is
our finding that this intervention may not be beneficial in
patients with advanced stages of the disease, unless
significant residual beta cell mass is present. Investigation
of the underlying immunological mechanisms revealed
enhancement of IFNγ, IL-10 and to lesser extent IL-4
production by Tregs in the spleen and the pancreatic draining
lymph nodes (PDLN). Interestingly, IFNγ and IL-10, but not
IL-4 were required for the protective effect. Both populations,
Tregs (CD4
+CD25
+ cells) and IFNγ-producing cells, pos-
sessed long- or short-term regulatory properties respectively,
demonstrating that a dominant regulatory effect was opera-
tional. In summary, we report here that B:9-23/IFA immu-
nisation operates through Tregs that produce IFNγ and IL-
10, and is an effective immune intervention strategy with the
ability to halt diabetes progression at advanced stages of
insulitis, but not long after disease is established.
Methods
Mice NOD/LtJ and NOD/IL-4
−/− female mice were pur-
chased from Jackson Laboratories (Bar Harbor, ME, USA).
All mice were maintained at La Jolla Institute for Allergy
and Immunology animal facility under pathogen-free
conditions and handled in accordance with protocols
approved by the organisation’s Animal Care and Use
Committee.
Blood glucose monitoring Blood glucose was monitored
twice a week with a monitoring system (OneTouch Ultra;
LifeScan, Milpitas, CA, USA). Diabetes was defined as two
consecutive blood glucose values above 13.9 mmol/l.
Definition of treatment groups Mice with blood glucose
<10 mmol/l at 4 or 9 weeks of age were characterised as
prediabetic stages I and II respectively. Mice older than
10 weeks of age with blood glucose 10 to 13.9 mmol/l at
first reading were defined as prediabetic stage III and those
with blood glucose 13.9 to 19.4 mmol/l as recent-onset
diabetes. Mice with blood glucose 19.4 to 33.3 mmol/l were
characterised as established diabetes.
B:9-23 peptide treatments B:9-23 peptide (amino acid
sequence: SHLVEALYLVCGERG) was purchased from
Αbgent (San Diego, CA, USA) with more than 95% wt/wt
purity. After dissolving in DMSO/DPBS, it was emulsified
in IFA (1:1) at 0.5 mg/ml. Injections of 200 µl (100 µg)
were performed s.c. at the neck area. This was done once in
each mouse at either 5 or 9 weeks of age, or when blood
glucose exceeded 10 mmol/l. In control groups, mice were
treated with DMSO/PBS/IFA or left untreated.
Flow cytometry A f t e ra2 . 4G 2b l o c k i n gs t e p ,c e l l sw e r e
stained for CD4-PacificBlue CD8α-APCCy7 (BD-
Pharmingen, San Diego, CA, USA), and CD25-FITC
and CD127-PeCy7 (eBioscience, San Diego, CA, USA).
For intracellular forkhead box p3 (FOXP3) detection,
cells were fixed with Fix/Perm buffer and stained with
FOXP3-antigen-presenting cell (APC; eBioscience). For
intracellular cytokine staining (ICCS), cells were initially
surface-stained with CD4-PerCP5.5, CD25-APCCy7 and
CD8a-PECy7, and then fixed and stained for IL-10-APC
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using a kit (Cytofix/Cytoperm; BD Biosciences) accord-
ing to manufacturers’ instructions. For NRP-V7 staining,
cells were stained with 1:100 NRP-V7-PE tetramer [23]a t
room temperature for 30 min. An antibody cocktail
containing CD44-PacificBlue (Biolegend, San Diego,
CA, USA), and CD4-PerCP5.5, CD19-FITC and CD8-
APC (BD-Pharmingen) was added and another incuba-
tion step followed. All antibody incubations were
performed at 4°C for 30 min (isotype controls were
included). Cells were immediately acquired on a flow
cytometer (LSRII; BD Biosciences) and analysed using a
software package (FlowJo; Treestar, Ashland, OR, USA).
Assessment of cytokine production by single lymphoid
cells All antibodies against IL-10, IL-4 and IFNγ were
from BD-Pharmingen except those for IL-17 (eBioscience).
Briefly, 96-well millititer HA plates (Millipore, Bedford,
MA, USA) were coated with capture antibodies at 5 µg/ml.
After a 10% (vol./vol.) FCS/HL-1 blocking step, CD8-
depleted (clone 53-6.7; BD-Pharmingen) splenocyte sus-
pensions were added at various dilutions ranging from 1×
10
6 to 0.125×10
6 cells/well and cultured in 2.5% (vol./vol.)
FCS/HL-1 medium. Cells from blood or PDLN were plated
at 0.25×10
6 cells/well. T cell-depleted splenocytes were
added as APCs from age-matched non-treated NOD mice at
a 1:1 ratio. B:9-23 peptide (10 µg/ml) was used in the
presence of rhIL-2 (50 U/ml). After 2 days incubation at 37°C
and extensive washes, detection antibodies were added at
4 µg/ml in PBS/Tween/1% (vol./vol.) FCS. Following an
avidin-peroxidase step (1:1,000 dilution; Vector Laboratories,
Burlingame, CA, USA,) colour was developed with 3-amino-
9-ethylcarbazole (Sigma-Aldrich, St Louis, MO, USA) and
H2O2. Finally, plates were rinsed in water, left to air-dry and
spots representing cytokine-producing cells were counted
using computer-assisted image analysis (Elispot reader; Carl
Zeiss MicroImaging, Thornwood, NY, USA).
Immunohistochemistry Pancreases were immersed in
Tissue-Tek OCT (Bayer, Torrance, CA, USA), quick-
frozen and cut into 6 µm tissue sections. After sections
were fixed in 100% vol./vol. acetone and dried, they were
re-hydrated in TBS and an avidin/biotin-blocking step was
included (Vector Laboratories). To detect insulin and CD4
or CD8 in pancreatic sections, primary antibodies were
applied as follows: guinea pig anti-swine insulin (1:300;
Dako, Carpinteria, CA, USA), and anti-CD4 (RM4.5) or
anti-CD8α (Ly-2) immunohistochemistry (1:50; BD-
Pharmingen). Primary and biotinylated secondary anti-
bodies were added and colour reaction was obtained by
sequential incubation with avidin-peroxidase and 3-amino-
9-ethylcarbazole, or alkaline phosphatase and Vector Blue
AP III (SK-5300) (Vector Laboratories).
Immunofluorescent staining For evaluation of pancreatic
cell division, sections were fixed for 15 min in 0.4% (wt/
vol.) paraformaldehyde. Concomitantly to anti-insulin, rat
anti-Ki-67 (1:100; Dako) and hamster anti-CD3-PE (BD-
Pharmingen) were used. Detection was achieved by highly
cross-adsorbed goat anti-guinea pig Alexa-647 and highly
cross-adsorbed goat anti-rat Alexa-488 (Invitrogen, Carls-
bad, CA, USA). The hamster anti-PE primary antibody was
added after incubation with these detection antibodies to
entirely eliminate cross-detection. Sections were mounted
with Prolong Antifade reagent (Invitrogen) and images
were captured with a confocal microscope (SP5; Leica,
Wetzlar, Germany) equipped with a 20×/0.70 numerical
aperture immersion objective (Leica). Renormalisation and
background subtraction was performed using ImageJ
software (http://rsbweb.nih.gov/ij/).
Histological scoring Insulitis scoring was performed
according to the following criteria: (1) severe insulitis or
score of 4 to 5, 50% or more of the islet area is infiltrated;
(2) mild insulitis or score of 2 to 3, <50% of the islet area is
infiltrated; (3) periinsulitis and no insulitis or score of 0 to
1, infiltration is restricted to the periphery of islets or
absence of cell infiltration.
In vitro stimulation and adoptive transfer experiments Lym-
phocytes from >35-week-old B:9-23/IFA-protected mice
were pooled. Following a CD8-depletion step, cells were
resuspended at 10 × 10
6/ml in 10% vol./vol. RPMI
containing 50 U/ml rhIL-2 and 10 μg/ml B:9-23, and
cultured for 3 days. Next, CD4
+ cells were purified and: (1)
stimulated for ICCS; or (2) further purified into
CD4
+CD25
+ or CD4
+CD25
−, or into IFNγ
+ and IFNγ
−
fractions. For ICCS, CD4
+ cells were stimulated with plate-
bound anti-CD3 (5 μg/ml) and soluble anti-CD28 (2.5 μg/
ml) for 4 to 16 h with brefeldin A (10 μg/ml). CD4
+CD25
+
or CD4
+CD25
− cells were isolated with a kit (CD4
+CD25
+
Regulatory T cell Isolation Kit; Miltenyi Biotech, Auburn,
CA, USA). For purification of IFNγ-producing cells, the
total CD4
+ cell fraction was stimulated in vitro with plate-
bound anti-CD3 (4 μg/ml) and soluble anti-CD28 (2 μg/ml)
for ∼14 h. IFNγ
+ vs IFNγ
− cells were collected using a
mouse IFNγ secretion assay (Miltenyi Biotech) according
to instructions. At least 1×10
6 total purified lymphocytes
were adoptively transferred i.v. into 8- to 9-week-old NOD
animals.
Antibody treatments Anti-IL-10 (clone JES5-2A5) and
anti-IFNγ (clone XMG1.2) were purchased from BD-
Pharmingen. Mice (9 weeks old) were immunised with B:9-
23/IFA and subsequently treated with 125 μga n t i b o d yi . p .
Thiswasdonetwice at11andtwice 12weeks ofage,totalling
four times (plus control [rat anti-mouse IgG1 isotype]). Mice
1960 Diabetologia (2010) 53:1958–1970receiving CD4
+CD25
+ T cells anti-IFNγ treatments started
the next day (two times a week for 2 weeks).
Statistical analysis Data are expressed as a mean ± SD.
The statistical significance of the difference between
means was determined using the two-tailed Student’s t
test or the logrank test. Statistical tests were conducted
with PRISM software (Graphpad, San Diego, CA, USA),
with significance defined as *p<0.05, **p<0.01 and
***p<0.001.
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Fig. 1 Insulin B:9-23/IFA treatment given at all prediabetic stages
protects from diabetes. a Percentage of NOD mice developing
diabetes after a single 100 μg B:9-23/IFA s.c. injection (blue line) at
9 weeks of age (n=14) vs mice that were left untreated (black line, n=
14) or were treated with PBS/IFA (red line, n=12). p<0.001. b As in
a, but with immunisation at 5 weeks of age (n=12 per group). All
mice were monitored for blood glucose from 10 to >35 weeks of age.
Each immunisation protocol was repeated in at least two independent
experiments. p<0.01 compared with non-treated mice. Red arrows,
time of immunisation. c Individual blood glucose represented by
differently coloured lines after B:9-23/IFA treatment at 9 weeks of
age. One mouse that remained hyperglycaemic for more than three
consecutive measurements was killed at 18 weeks of age. d Individual
mice were treated with a single s.c. B:9-23/IFA injection when blood
glucose was >10 mmol/l. Red triangles, individual entry blood glucose
of mice progressing to diabetes; blue squares, entry blood glucose of
mice that maintained normoglycaemia. Dashed line (c, d) indicates
cut-off blood glucose value by which mice were considered diabetic
Table 1 B:9-23/IFA treatment s.c. protects normoglycaemic mice from diabetes development
Treatment group Blood glucose
(mmol/l)
Mice
treated (n)
Mice
protected (n)
Mice
protected (%)
Diabetic
mice (n)
Diabetic
mice (%)
Mice
fluctuating
a (n)
Mice fluctuating
a
(%)
Prediabetic stage I
b <6.6 12 9 75 3 25 0 0
Prediabetic stage II
c <6.6 14 12 85.7 1 7.15 1 7.15
Prediabetic stage III
d 10–13.9 19 10 52.63 7 36.842 2 10.53
Recent-onset
e 13.9–19.4 11 0 0 8 72.728 3 27.273
Established diabetes
e 19.4–33.3 7 0 0 7 100 0 0
Values are ranges unless otherwise indicated
aBlood glucose fluctuated for several weeks above and below 13.9 mmol/l before mice turned diabetic
b4 weeks old;
c9 weeks old;
d10 weeks old;
eolder than 10 weeks
Diabetologia (2010) 53:1958–1970 1961Results
B:9-23/IFA immunisation s.c. can protect from advanced
insulitis but not established diabetes Without intervention
in the NOD mouse, islet destruction becomes evident by
4 weeks of age, with more islets becoming inflamed as the
disease progresses. In our facility, diabetes manifests by
10 weeks of age, and as the disease progresses, greater
numbers of insulin-producing beta cells are destroyed until
more than 70 to 80% of the pancreatic islets are lost, which
coincides with clinical manifestation of the disease. The
anti-diabetogenic properties of B:9-23 peptide (100 μg s.c.)
Fig. 2 Insulin B:9-23/IFA treatment decreases insulitis without
enhancing beta cell proliferation. a Pancreatic sections from 12-week
old normoglycaemic control and B:9-23/IFA-treated mice were stained
for insulin/CD4 and scored for insulitis as described. Percentages
represent the number of islets of a given score (white, score 0–1; light
grey, score 2–3; dark grey, score 4–5) over the total number of islets
examined; at least six islets were examined per mouse (four mice per
group). p<0.01 for B:9-23/IFA vs PBS/IFA. b Pancreatic histology.
Sections were co-stained for insulin (blue) and CD8 or CD4 as
indicated (both red) and analysed at 10× magnification. c Pancreatic
sections from the same mice as above (a, b) were stained for Ki-67
(green), insulin (blue) and CD3 (red) and analysed with confocal
microscopy at 20× magnification. Representative Ki-67/insulin micro-
photographs showing the presence of Ki-67 cells within the pancreas
with several degrees of insulitis (as shown) were analysed per group.
White arrows, Ki-67
+/Ins
+ double-stained cells
1962 Diabetologia (2010) 53:1958–1970emulsified in IFA were compared in vivo in NOD mice at
prediabetic stages I and II, i.e. at 5 and 9 weeks of age,
respectively (Fig. 1a, b,T a b l e1). B:9-23/IFA immunisa-
tion in 9-week old NOD mice was as effective as
immunisation at 5 weeks of age. When blood glucose was
monitored, mice immunised with B:9-23/IFA displayed
significant fluctuations over a 25-week life span (Fig. 1c).
Following 25 weeks of fluctuating blood glucose, most
NOD mice treated remained stably normoglycaemic until
>35 weeks of age, underlining the potential long-term
benefit of this approach.
The above observations prompted us to test whether the
same regimen could suppress ongoing diabetes. Blood
glucose in NOD mice older than 10 weeks of age seems to
reflect the degree of ongoing insulitis or alternatively the
residual beta cell mass, i.e. mice with blood glucose
>13.9 mmol/l are considered to have more insulitis and
less beta cell mass than mice with blood glucose
<13.9 mmol/l. Therefore, as indicated in Table 1, mice
with blood glucose >10 mmol/l were divided into three
groups and treated with B:9-23/IFA. Our results show that
this type of intervention is moderately effective in mice at
prediabetic stage III and with blood glucose no greater than
13.9 mmol/l. Mice from this group remained below
13.9 mmol/l during the total period of observation. When
treated mice were plotted according to age, blood glucose at
the time of treatment and progression to diabetes, an
interesting trend emerged, namely that the earlier the
disease manifestation and the higher the blood glucose,
the more difficult it was to reverse hyperglycaemia
(Fig. 1d).
Treatment with B:9-23/IFA s.c. reduces insulitis without
enhancing beta cell proliferation To determine the extent
of pancreatic tissue destruction following B:9-23/IFA
immunisation, pancreases from 12-week-old non-diabetic
mice immunised at 9 weeks of age were examined
histologically. As indicated in Fig. 2a, b, the majority of
islets in animals treated with B:9-23/IFA were minimally
inflamed or had mild peri-insulitis. In contrast, most islets
from mice that were treated or not with PBS/IFA had a
much higher level of CD4
+ and CD8
+ cell infiltrates.
Scoring of the islets showed that mice immunised with B:9-
23/IFA had a much lower degree of insulitis than the
control mice. Interestingly, PBS/IFA immunisation also
resulted in some reduced inflammation compared with non-
treated animals, suggesting that IFA alone is capable of
affecting the diabetogenic process to some degree in the
NOD mouse.
B:9-23 immunotherapy s.c. (1) preserved greater numb-
ers of non-inflamed islets; (2) did not establish normal
blood glucose during the first post-immunisation period in
prediabetic NODs; and (3) restored normoglycaemia in
some prediabetic stage III NOD mice. We therefore sought
to address whether beta cell regeneration was involved. To
test this, pancreatic sections were co-stained for insulin and
Ki-67, and analysed histologically. Interestingly, as shown
in Fig. 2c, few Ki-67/insulin double-positive beta cells
could be detected, irrespective the treatment. Thus, we
concluded that B:9-23/IFA immunisation did not affect beta
cell replication, but instead modulated the autoreactive
immune response, an observation that also explains why
this regimen is not effective at more advanced stages of the
disease, when greater beta cell mass is lost.
B:9-23/IFA therapy augments Tregs and results in loss of
autoreactive CD8 cells We reasoned that an effect on Tregs
and autoaggressive leucocytes would explain the protection
from type 1 diabetes observed after B:9-23/IFA therapy.
The frequency of Tregs determined as CD4
+CD25
+
CD127
lowFOXP3
+ was followed in blood, spleen and
PDLN of mice immunised at 9 weeks of age. Approxi-
mately 2 to 3 weeks after immunisation, elevated Treg
frequencies and numbers were found in all compartments,
except for blood (Fig. 3a–c). These increases were also
evident when the total cell numbers in spleen or PDLN
were taken into account (Fig. 3d–e). Treg frequency at later
Fig. 3 Insulin B:9-23/IFA treatment induces Tregs that protect from
diabetes. a Treg (CD4
+CD25
+FOXP3
+CD127
low) frequency in the
PDLN, (b) spleen and (c) blood of NOD mice immunised with B:9-
23/IFA (white bars) or PBS/IFA (grey bars) s.c. at 9 weeks of age or
left untreated (black bars). Treg frequency in the blood was monitored
for 3 consecutive weeks after immunisation (as indicated), whereas in
PDLN and spleen Treg frequency was monitored for 2 consecutive
weeks as shown. The experiment was repeated at least twice with
three to four mice per group (ND, not done). p<0.05 for PDLN at
12 weeks and p<0.01 for spleen at 11 weeks of age when B:9-23/IFA
is compared with controls. d Total Treg numbers in PDLN and (e) the
spleen. The Treg percentage for each individual mouse was multiplied
with its respective total spleen or PDLN lymphocyte number. Trypan
blue staining was used to exclude dead cells. p<0.01 for PDLN at
12 weeks, p<0.05 and p<0.01 for spleen at 12 and 11 weeks of age
respectively (B:9-23/IFA vs controls). Mice analysed were those
analysed above (a–c). f Representative flow cytometry plots as
indicated in the PDLN and spleen at 12 weeks of age, indicating the
CD25
+FOXP3
+ cells after gating on CD4
+CD8
−CD127
low lympho-
cytes. g, h CD8-depleted lymphocytes from B:9-23/IFA-treated and
protected mice (>35 weeks) were pooled and cultured for 3 days in the
presence of B:9-23 (10 μg/ml) and rhIL-2 (50 U/ml). Subsequently,
CD4
+CD25
+ (Tregs) or CD4
+CD25
− T cells were isolated and
adoptively transferred to 8- to 9-week-old new prediabetic NOD
animals. The CD4/CD25 profile of the cells prior to purification is
shown above (g). h Diabetes incidence in NOD animals after
receiving >1×10
6 CD4
+CD25
+ or CD4
+CD25
− T cells i.v. Donor
cells were derived from mice treated at either 5 or 9 weeks of age;
CD25
+ n=8, CD25
− n=14; p<0.05. i Mean percentage and (j) total
number of NRP-V7
+CD8
+ cells in the spleen after gating on live
CD4
−CD19
− lymphocytes from 12-week-old mice immunised at
9 weeks of age with B:9-23/IFA and control. p<0.05
b
Diabetologia (2010) 53:1958–1970 19631964 Diabetologia (2010) 53:1958–1970time points, i.e. 6 to 7 weeks post immunisation was not
significantly higher than in control groups, although, in
controls, a significant reduction in total lymphocyte
numbers was seen, perhaps due to diabetes-associated
lymphopenia (data not shown). In adoptive transfer experi-
ments, in which CD4
+CD25
+ T cells from protected mice
were transferred i.v. into 8- to 9-week-old prediabetic NOD
mice, protection from diabetes was observed (Fig. 3g–h).
Culturing the cells with B:9-23 increased the total fraction
of CD4
+CD25
+ cells and enhanced their suppressive
activity, perhaps due to further enrichment with B:9-23-
specific cells (expansion greater than two- to threefold, cells
>50% FOXP3
+CD127
low, data not shown).
Since insulin is the initiating autoantigen in the NOD
mouse, but other autoantigens such as GAD65 are
recognised as the disease progresses [24], protection
after B:9-23/IFA immunisation in older NOD mice was
probably also mediated by bystander suppression mech-
anisms [25–28]. To test this premise, cells from spleens of
mice immunised with B:9-23/IFA were stained with the
MHC class I tetramer NRP-V7, which identifies diabeto-
genic CD8
+ Tc e l l s[ 23] .A ss h o w ni nF i g .3i–j,ag r e a t
reduction in NRP-V7
+CD8
+CD19
− cells was seen in
spleen, indicating that prevention of type 1 diabetes
through B:9-23/IFA immunisation resulted in loss of
NRPV-7 T cells.
20
15
10
5
0
20
15
10
5
0
80
70
60
50
40
30
20
10
0
25
20
15
10
5
0
IFNγ
IL-17
IL-4
IL-10
IFNγ
IL-17
IL-4
IL-10
IFNγ
IL-17
IL-4
IL-10 No treatment PBS/IFA B:9-23/IFA
PDLN Blood
Spleen Spleen
S
F
U
/
2
.
5
×
1
0
–
5
 
c
e
l
l
s
S
F
U
/
1
×
1
0
–
6
 
c
e
l
l
s
S
F
U
/
2
.
5
×
1
0
–
5
 
c
e
l
l
s
R
a
t
i
o
 
I
F
N
γ
/
I
L
-
1
7
ab
cd
Fig. 4 Insulin B:9-23/IFA treatment induces IFNγ/IL-4 production in
the spleen and IL-10/IL-4 in the PDLN. In B:9-23/IFA immunised
mice (white bars), laboratory measurements showed an increase in IL-
10 (p<0.05) and IL-4 (p<0.05) cytokine-producing cell numbers in
the PDLN (a), in IFNγ in the blood (p<0.05) (b), and in IFNγ and IL-
4 in the spleen (p<0.01 and p<0.05, respectively) (c) vs no treatment
(black bars) and PBS/IFA treatment (grey bars). In the spleen (d), the
IFNγ:IL-17 ratio was increased more than tenfold (p<0.01) The
number of B:9-23-reactive CD4
+ T cells producing IFNγ, IL-17, IL-4
and IL-10 in all secondary lymphoid organs analysed was calculated
by deducting the number of spot-forming units (SFU) without
stimulation from the number of SFU after B:9-23 re-stimulation. In
each condition, 50 U/ml of rhIL-2 was added to the culture, which
lasted for 3 days. In the spleen, Elispot using CD8-depleted
lymphocytes was performed, whereas in the blood and PDLN, T
cell-depleted splenocytes from age-matched non-treated NOD mice
were added as APCs. The numbers of SFU without stimulation
(background), which were subtracted to generate the experimental
results for IFNγ, IL-17, IL-4 and IL-10, were: for spleen 80±20,
150±45, 115±30 and 25±15; for PDLN 43±13, 75±25, 48±12 and
45±15; and for blood: 35±12, 75±15, 60±25 and 6±5, respectively.
The analysis shown is from 12-week-old immunised or non-treated
NOD animals; similar results were obtained from two independent
experiments with three mice per group. One representative experiment
is shown
Diabetologia (2010) 53:1958–1970 1965B:9-23 immunisation increases protective B:9-23-specific
IFNγ and IL-10 cytokine production In diabetes, a benefi-
cial outcome of immunisation has been frequently associated
with changes in the endogenous cytokine microenviron-
ment. A shift from pathogenic to protective (IL-4, IL-10)
cytokine production has been described [29, 30]. Mice
immunised with B:9-23/IFA were assessed by Elispot
analysis for the production of four cytokines: IL-10, IL-4,
IFNγ and IL-17. As shown in Fig. 4, upon in vitro re-
stimulation with the B:9-23 peptide, an increase of IFNγ
cytokine-producing cells in the spleen and of IL-10 in the
PDLN was seen. Elevation of IL-4 production in both
lymphoid compartments was also observed. In addition,
when the number of IFNγ-producing cells for individual
mice was divided by the number of Th17 cells and
averaged per experimental group, a strong increase in the
IFNγ:IL-17 ratio in the spleen of mice immunised with
B:9-23/IFA was seen (Fig. 4d).
Based on our Elispot results, IL-4, IFNγ and IL-10
were good candidates for mediating the protection
offered by B:9-23/IFA immunisation. To test this in
vivo, mice receiving B:9-23/IFA injections were treated
twice i.p. with anti-IL-10 or anti-IFNγ neutralising
antibodies. Interestingly, neutralisation of either cytokine
following B:9-23/IFA treatment restored normal progres-
sion towards diabetes in the NOD mouse (Fig. 5a). In
contrast, IL-4 was not required for protection, since B:9-
23/IFA immunisation was as effective in IL-4-deficient
NOD as in wild-type mice (Fig. 5b). NOD mice in which
anti-IL-10 or anti-IFNγ neutralisation was performed at
the same age showed similar kinetics of diabetes devel-
opment (data not shown). Thus, B:9-23/IFA protection
induces IL-10 and IFNγ, which are required for establish-
ing tolerance.
B:9-23/IFA-induced IFNγ supports the suppressive activity
of CD4
+CD25
+ cells and shows immunomodulatory
action The potential role of IFNγ during tolerance re-
establishment in diabetes is not well known. Interestingly,
as shown in Fig. 6a, upon in vitro re-stimulation with plate-
bound anti-CD3 and soluble anti-CD28, CD4
+CD25
+ and
CD4
+CD25
− populations were both able to produce IFNγ
and IL-10, with CD4
+CD25
+ Tregs producing ten times
more. Intracellular co-staining for FOXP3 showed signif-
icant IFNγ production by this population, although
FOXP3 levels were reduced within the CD4
+CD25
+
population after anti-CD3/CD28 stimulation (Fig. 6a).
When IFNγ production was blocked after CD4
+CD25
+
(Treg) transfer, the protective effect was abolished
(Fig. 6b). These results show that B:9-23/IFA immunisa-
tion induces Tregs that can modulate the function or
differentiation of diabetogenic effector T cells through
IFNγ production.
To further elucidate the immunoregulatory properties of
IFNγ, CD4
+IFNγ
+ cells were adoptively transferred into
new 8- to 9-week-old prediabetic hosts. It was found that
this population of cells was able to delay, but not protect
NOD recipients from diabetes development (Fig. 6c, d). On
the other hand, IFNγ
− cells failed to convey any protection,
causing instead some acceleration of the disease. The fact
that CD4
+IFNγ
+ cell transfer led to only transient protec-
tion from diabetes development could imply that (1) the
number of cells transferred was limited (less than 1×10
6
cells/recipient), (2) pathogenic cells were also enriched, (3)
too few regulatory cells were enriched or (4) the regulatory
properties of those cells were lost with time.
Fig. 5 The protective effect of B:9-23/IFA is mediated by IFNγ and
IL-10, but not by IL-4 production. a Percentage of mice developing
diabetes upon in vivo neutralisation of IFNγ (light grey line) or IL-10
(dark grey line) after s.c. treatment with insulin B:9-23/IFA of 9-week
old NODs. Control, B:9-23/IFA treated with the isotype anti-rat IgG
(black line) or PBS/IFA alone (dashed black line) are also depicted.
Mice were treated for both neutralising antibodies with two intraper-
itoneal injections per week, at 10 and 11 weeks of age. Anti-IFNγ
(clone XMG1.2), anti-IL-10 (clone JES5-2A5) or isotype control were
given to mice (150 µg per animal per injection) i.p. The mice received
a total of four antibody injections. b Diabetes progresses normally in
Il-4
−/− NOD mice (light grey line), similarly to Il-4
−/− NOD mice
treated with PBS/IFA (dashed black line) and IL4 wild type (WT)
controls (black line). Upon B:9-23/IFA immunisation tolerance is
achieved irrespective of endogenous IL-4 levels (black line). At least
12 mice were included in each experimental group. p<0.01 compared
with WT
1966 Diabetologia (2010) 53:1958–1970Discussion
Subcutaneous B:9-23/IFA treatment can effectively prevent
diabetes when given at an early stage during disease
development in NOD mice [14, 15]. Translation of this
intervention to humans is in progress in early clinical trials
[31], but it is not well known how the precise disease stage
would affect therapeutic efficiency. In our study, B:9-23/
IFA immunisation given at more advanced prediabetic
stages significantly protected NOD mice from diabetes
development, albeit to a less pronounced degree in mice
with higher (non-physiological) blood glucose values (10–
13.9 mmol/l). However, this intervention was not effica-
cious in mice that had established signs of diabetes and
greater loss of beta cell mass, probably because B:9-23/IFA
was not able to increase beta cell regeneration. Histological
examination of mouse pancreases showed reduced lympho-
cytic infiltration, which was not associated with islet
proliferation, suggesting that this intervention predominantly
affected the autoaggressive effector response. This was due to
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Fig. 6 CD4
+CD25
+ insulin
B:9-23/IFA-induced cells
(Tregs) mediate protection
against diabetes through IFNγ
production. a Lymphocytes
from protected B:9-23/IFA
immunised mice were pooled
and cultured for 3 days in the
presence of B:9-23 (10 μg/ml)
and rhIL-2 (50 U/ml). Subse-
quently, cells were stimulated
for 4 h with plate-bound aCD3
(5 μg/ml) and soluble aCD28
(2.5 μg/ml), and assayed for
cytokine production. The IL-10/
IFNγ as well as the FOXP3/
IFNγ profile after gating on the
CD4
+CD25
+ and CD4
+CD25
−
populations is shown. The iso-
type control for both cytokines
is also shown for the
CD4
+CD25
+ population.
b Upon adoptive transfer of
CD4
+CD25
+ cells from pro-
tected mice, some (n=6) re-
ceived two anti-IFNγ (clone
XMG1.2) neutralising antibody
injections (150 μg/each), one at
10 and the other at 11 weeks of
age. At the time of adoptive
transfer, recipients were 8 to
9 weeks old. Total i.p. injections
per recipient, n=4. c Cells from
above procedure (a) were sorted
into CD4
+IFNγ
+ (black line) or
CD4
+IFNγ
− (grey line) popula-
tions as described above.
d Approximately 1×10
6 of cells
were adoptively transferred
to 8- to 9-week-old prediabetic
NOD mice and diabetes
incidence was followed; n=14
for IFNγ
+ cells (grey line),
n=12 for no treatment (black
line) and n=10 for IFNγ
− cells
(black dashed line)
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IL-4 to be operational in vivo. Our findings are of particular
interest for the ongoing B:9-23/IFA human trial, since
induction of such Tregs could hopefully be tracked in
human blood and serve as a correlate of successful
immunisation and, in the future, maybe even as a secondary
trial outcome.
It is likely that B:9-23/IFA immunisation mainly affected
endogenous beta cell-specific, regulatory (protective) im-
mune responses. This involved shifts in cytokine produc-
tion and was associated with reduction of auto-reactive T
cells of other specificities, such as IGRP-specific CD8
lymphocytes. The immune response against IGRP in NOD
mice was also reduced in another study in which tolerance
was achieved with intranasal proinsulin [32]. Tregs in
general play key roles in controlling many autoimmune
processes. They can be identified by high levels of FOXP3
and IL-2Rα (CD25) and/or production of certain immuno-
regulatory cytokines [33, 34]. Their suppressive activity can
be mediated by cell-to-cell contact or through cytokine
production, with cytotoxic T lymphocyte antigen 4 (CTLA-
4), IL-10 and TGF-beta-1 being the most important
mediators of their function in vivo [35–38]. In our study,
augmented Tregs were found 2 to 3 weeks after immunisa-
tion (Fig. 3a–c). Whether these Tregs represent a de novo
generated population from naive precursors or an expansion
of the endogenous population is not known.
An increase in antigen-specific IFNγ, IL-4 and IL-10
production coincided with the time of Treg induction, since
enhancement of B:9-23-specific IFNγ, IL-4 and IL-10
cytokine producing cells was seen 3 weeks after immunisa-
tion (Fig. 4). Neutralisation of IL-10 and IFNγ reversed
protection, resulting in hyperglycaemia. Blocking IFNγ
could also have diminished the action of autoaggressive
lymphocytes, but in that case protection from disease
after B:9-23/IFA treatment would still be seen. In order
to address the contribution of IL-4 production to
tolerance induction after B:9-23/IFA treatment, NOD/
Il4
−/− mice were used. In these mice, progression to
diabetes was still prevented after B:9-23/IFA treatment,
suggesting that IL-4 production is not necessary for
achieving tolerance. The contribution of TGF-beta-1 was
not directly addressed in the present study, but its
importance in mediating antigen-specific tolerance has
been shown previously [39–41].
In order to further elucidate the immunomodulatory
potential of the B:9-23-induced Tregs, cells from protected
donors were isolated, expanded in vitro, separated into
CD4
+CD25
+ and CD4
+CD25
− fractions and adoptively
transferred into prediabetic hosts. The in vitro culture step
seemed to be important for enhancing CD4
+CD25
+ regula-
tory properties, perhaps due to an increase in B:9-23-specific
Treg qualities. Inclusion of cells from age-matched control
mice was not possible since more than 90% of them
developed diabetes, while cells from the remaining ones
failed to grow under the same culture conditions. Additional
analysis revealed a link between IFNγ/IL-10 production and
Tregs, in that the CD4
+CD25
+ B:9-23-expanded cells were
high producers of both cytokines, but not co-producers. In
follow-up studies, IFNγ production was associated with
protection from diabetes in CD4
+CD25
+ cell transfers. Recent
evidence suggests that IFNγ can be important for protection
from diabetes and other autoimmune diseases [42–46]. More
recently in diabetes, IFNγ production was shown to suppress
the pathogenic activity of Th17 cells [47]. Upon B:9-23/IFA
immunisation, we observed neither strong induction nor
significant reduction of IL-17 production. While IL-17 levels
remained constant, IFNγ production and the IFNγ:IL-17
ratio were increased. To further understand the contribution of
IFNγ in B:9-23/IFA-induced tolerance, adoptive transfers
with cells enriched in IFNγ production were done. A delay in
disease progression was seen, suggesting that this population
has at least transient regulatory properties and that other Tregs
or other IL-10-producing cells are necessary for establishing
prolonged tolerance.
In conclusion, IFNγ and IL-10 are important mediators of
B:9-23/IFA-induced tolerance. Additional analyses will be
required to understand the precise role of inflammatory
c y t o k i n e ss u c ha sI F N γ in Treg-mediated suppression of
autoimmunity. To date, treatment with anti-CD3 antibody
alone or in conjunction with nasal (pro)insulin therapy has
been shown to reverse diabetes and to suppress disease
recurrence[48]. The capacity of InsB:9-23/IFA immunisation
to reverse diabetes as a monotherapy or in conjunction with
other drugs such as Abatacept (CTLA4-Ig) has not yet been
tested. It is also possible that as antigens spread with disease
progression, a combination of more than one autoantigen
such as GAD65, GAD2 and IA-2 may be necessary to
induce tolerance [13, 49]. Ideally, the use of more aggressive
immunomodulatory regimens should be limited in time and
dose, thus avoiding some of their negative side effects. This
can be achieved by combining antigen-specific interventions
with systemically acting agents.
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